Header Logo

Connection

Hua Chen to United States

Back to Details
This is a "connection" page, showing publications Hua Chen has written about United States.
Hua Chen
Connection Strength
3.248
United States
  1. Trends in Repeat Opioid Analgesic Prescription Utilization for Acute Pain in Children: 2013-2018. Acad Pediatr. 2024 07; 24(5):776-782.
    View in: PubMed
    Score: 0.182
  2. Association Between Initial Opioid Prescription Duration and 30-Day Risk of Receiving Repeat Opioid Among Children. Acad Pediatr. 2023 03; 23(2):416-424.
    View in: PubMed
    Score: 0.168
  3. Risk of asthma exacerbation associated with opioid and nonopioid analgesic use in children with current asthma. J Manag Care Spec Pharm. 2022 Mar; 28(3):325-335.
    View in: PubMed
    Score: 0.163
  4. Impact of geographic access to primary care providers on pediatric behavioral health screening. Prev Med. 2021 12; 153:106856.
    View in: PubMed
    Score: 0.159
  5. Utilization of opioid versus non-opioid analgesics in Medicaid and CHIP enrolled children with current asthma. Pharmacoepidemiol Drug Saf. 2021 Nov; 30(11):1520-1531.
    View in: PubMed
    Score: 0.157
  6. Association of the Healthcare Effectiveness Data and Information Set (HEDIS) Follow-Up Care Measures and Medication Adherence Among Medicaid Insured Children with ADHD. J Atten Disord. 2022 Feb; 26(3):370-376.
    View in: PubMed
    Score: 0.151
  7. Racial/ethnic differences in treatment quality among youth with primary care provider-initiated versus mental health specialist-initiated care for major depressive disorders. Child Adolesc Ment Health. 2020 02; 25(1):28-35.
    View in: PubMed
    Score: 0.140
  8. Physician Care Coordination and the Use of Psychotropic Polypharmacy in the Management of Pediatric Mental Disorders. J Manag Care Spec Pharm. 2019 Jan; 25(1):29-38.
    View in: PubMed
    Score: 0.131
  9. Risk factors of psychotropic polypharmacy in the treatment of children and adolescents with psychiatric disorders. Res Social Adm Pharm. 2019 04; 15(4):395-403.
    View in: PubMed
    Score: 0.126
  10. Racial/ethnic differences in the treatment of adolescent major depressive disorders (MDD) across healthcare providers participating in the medicaid program. J Affect Disord. 2018 08 01; 235:155-161.
    View in: PubMed
    Score: 0.124
  11. Effect of Psychopharmacotherapy on Body Mass Index Among Children and Adolescents with Bipolar Disorders. J Child Adolesc Psychopharmacol. 2017 May; 27(4):349-358.
    View in: PubMed
    Score: 0.116
  12. Risk of manic switch associated with antidepressant therapy in pediatric bipolar depression. J Child Adolesc Psychopharmacol. 2014 Dec; 24(10):551-61.
    View in: PubMed
    Score: 0.099
  13. Comparative effectiveness of monotherapy with mood stabilizers versus second generation (atypical) antipsychotics for the treatment of bipolar disorder in children and adolescents. Pharmacoepidemiol Drug Saf. 2014 Mar; 23(3):299-308.
    View in: PubMed
    Score: 0.093
  14. The utilization of psychopharmacological treatment and medication adherence among Medicaid enrolled children and adolescents with bipolar depression. J Affect Disord. 2013 Sep 05; 150(2):424-9.
    View in: PubMed
    Score: 0.089
  15. Risk of pneumonia in elderly nursing home residents using typical versus atypical antipsychotics. Ann Pharmacother. 2013 Apr; 47(4):464-74.
    View in: PubMed
    Score: 0.088
  16. Risk of death in dual-eligible nursing home residents using typical or atypical antipsychotic agents. Med Care. 2012 Nov; 50(11):961-9.
    View in: PubMed
    Score: 0.085
  17. Factors associated with the use of immune checkpoint inhibitors in older adults with metastatic non-small cell lung cancer and pre-existing autoimmune disease: A SEER-Medicare study. J Geriatr Oncol. 2024 11; 15(8):102071.
    View in: PubMed
    Score: 0.049
  18. Impact of adherence on the cost-effectiveness of apixaban and rivaroxaban in stroke prevention among patients with atrial fibrillation in the United States. Expert Rev Pharmacoecon Outcomes Res. 2025 Jan; 25(1):63-70.
    View in: PubMed
    Score: 0.049
  19. Group-based trajectory modeling to identify adherence patterns for direct oral anticoagulants in Medicare beneficiaries with atrial fibrillation: a real-world study on medication adherence. Int J Clin Pharm. 2024 Dec; 46(6):1525-1535.
    View in: PubMed
    Score: 0.048
  20. Development and internal validation of a risk prediction model for HIV disease severity among people living with HIV and mental illness or substance use disorder. Ann Epidemiol. 2023 11; 87:79-92.
    View in: PubMed
    Score: 0.045
  21. Rethinking access to care: A spatial-economic analysis of the potential impact of pharmacy closures in the United States. PLoS One. 2023; 18(7):e0289284.
    View in: PubMed
    Score: 0.045
  22. Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study. Cancer. 2023 04 01; 129(7):1051-1063.
    View in: PubMed
    Score: 0.044
  23. Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2- metastatic breast cancer in the United States. Breast Cancer Res Treat. 2023 Feb; 198(1):159-166.
    View in: PubMed
    Score: 0.043
  24. Patterns of Lipid Lowering Therapy Use Among Older Adults in a Managed Care Advantage Plan in the United States. J Pharm Pract. 2024 Feb; 37(1):123-131.
    View in: PubMed
    Score: 0.043
  25. Evaluating adherence to concomitant diabetes, hypertension, and hyperlipidemia treatments and intermediate outcomes among elderly patients using marginal structural modeling. Pharmacotherapy. 2022 07; 42(7):518-528.
    View in: PubMed
    Score: 0.042
  26. Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study. Drugs Aging. 2022 06; 39(6):453-465.
    View in: PubMed
    Score: 0.042
  27. Risk of overactive bladder associated with cholinesterase inhibitors in dementia. J Am Geriatr Soc. 2022 03; 70(3):820-830.
    View in: PubMed
    Score: 0.040
  28. Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study. Curr Med Res Opin. 2021 08; 37(8):1303-1313.
    View in: PubMed
    Score: 0.039
  29. Antipsychotic Initiation Among Older Dementia Patients Using Cholinesterase Inhibitors: A National Retrospective Cohort Study. Drugs Aging. 2021 06; 38(6):493-502.
    View in: PubMed
    Score: 0.038
  30. Risk of Cardiovascular Outcomes and Antihypertensive Triple Combination Therapy Among Elderly Patients with Hypertension Enrolled in a Medicare Advantage Plan (MAP). Am J Cardiovasc Drugs. 2020 Dec; 20(6):591-602.
    View in: PubMed
    Score: 0.037
  31. Cost-effectiveness analysis of antihypertensive triple combination therapy among patients enrolled in a Medicare advantage plan. Expert Rev Pharmacoecon Outcomes Res. 2021 Aug; 21(4):829-836.
    View in: PubMed
    Score: 0.037
  32. A retrospective study of drug utilization and hospital readmissions among Medicare patients with hepatic encephalopathy. Medicine (Baltimore). 2020 Apr; 99(16):e19603.
    View in: PubMed
    Score: 0.036
  33. Risk of Mortality Associated With Atypical Antipsychotic use: A National Cohort Study of Older Adults With Depression and Parkinson's Disease. Am J Geriatr Psychiatry. 2020 10; 28(10):1079-1088.
    View in: PubMed
    Score: 0.035
  34. Risk of Mortality Associated with Non-selective Antimuscarinic medications in Older Adults with Dementia: a Retrospective Study. J Gen Intern Med. 2020 07; 35(7):2084-2093.
    View in: PubMed
    Score: 0.035
  35. Risk of pneumonia associated with atypical antipsychotic use in nursing home residents with Parkinson's disease. J Psychiatr Res. 2019 10; 117:116-121.
    View in: PubMed
    Score: 0.034
  36. Medication Adherence to Antihypertensive Triple-Combination Therapy Among Patients Enrolled in a Medicare Advantage Plan. J Manag Care Spec Pharm. 2019 Jun; 25(6):678-686.
    View in: PubMed
    Score: 0.034
  37. Anticholinergic burden and risk of cognitive impairment in elderly nursing home residents with depression. Res Social Adm Pharm. 2020 03; 16(3):329-335.
    View in: PubMed
    Score: 0.034
  38. The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer. 2019 04 01; 125(7):1155-1162.
    View in: PubMed
    Score: 0.033
  39. Risk of Mortality Associated with Anticholinergic Use in Elderly Nursing Home Residents with Depression. Drugs Aging. 2017 09; 34(9):691-700.
    View in: PubMed
    Score: 0.030
  40. The Prevalence of and Factors Associated With Receiving Concurrent Controlled Substance Prescriptions. Subst Use Misuse. 2017 Oct 15; 52(12):1639-1645.
    View in: PubMed
    Score: 0.029
  41. The Impact of Pharmacotherapy on Substance Use in Adolescents With Attention-Deficit/Hyperactivity Disorder: Variations Across Subtypes. Subst Use Misuse. 2017 08 24; 52(10):1266-1274.
    View in: PubMed
    Score: 0.029
  42. Risk of Mortality in Elderly Nursing Home Patients with Depression Using Paroxetine. Pharmacotherapy. 2017 03; 37(3):287-296.
    View in: PubMed
    Score: 0.029
  43. Anticholinergic Medication Use and Risk of Fracture in Elderly Adults with Depression. J Am Geriatr Soc. 2016 07; 64(7):1492-7.
    View in: PubMed
    Score: 0.027
  44. Anticholinergic Medication Use and Risk of Dementia Among Elderly Nursing Home Residents with Depression. Am J Geriatr Psychiatry. 2016 06; 24(6):485-95.
    View in: PubMed
    Score: 0.027
  45. Anticholinergic Medication Use and Risk of Pneumonia in Elderly Adults: A Nested Case-Control Study. J Am Geriatr Soc. 2016 Feb; 64(2):394-400.
    View in: PubMed
    Score: 0.027
  46. Comparative Cognitive Profile of Second-Generation Antidepressants in Elderly Nursing Home Residents With Depression. Ann Pharmacother. 2016 Feb; 50(2):96-105.
    View in: PubMed
    Score: 0.026
  47. Risk of Dementia Among Elderly Nursing Home Patients Using Paroxetine and Other Selective Serotonin Reuptake Inhibitors. Psychiatr Serv. 2015 Dec 01; 66(12):1333-40.
    View in: PubMed
    Score: 0.026
  48. Concurrent use of stimulants and second-generation antipsychotics among children with ADHD enrolled in Medicaid. Psychiatr Serv. 2015 Apr 01; 66(4):404-10.
    View in: PubMed
    Score: 0.025
  49. Antihypertensive drug use and the risk of dementia in patients with diabetes mellitus. Alzheimers Dement. 2012 Sep; 8(5):437-44.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.